CIRM gives industry just $30m from $3bn stem cell research funds
This article was originally published in Scrip
The California Institute for Regenerative Medicine (CIRM) answered the biotechnology industry's request for a bigger slice of the state's $3 billion stem cell research funding pie with a $30 million grant program that will give up to $10 million each to three development programmes that can complete a clinical trial in patients within the next four years. That may not be enough for some in the industry.
You may also be interested in...
Private Company Edition: TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds.
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.